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Background: In a national multicenter phase III study in stage IIIB and 
IV NSCLC patients, comparison of three cycles of vinorelbine/carbo-
platin (VC) to three cycles of gemcitabine/carboplatin (GC) concluded 
with equal survival in the two treatment arms. Hematological toxicity 
requiring interventions was more frequent in the GC arm but signiﬁ-
cant differences in quality of life (QOL) were not revealed. PS2 is the 
most powerful predictor of survival in patients with advanced NSCLC. 
Since single drug or combination chemotherapy to PS2 patients with 
advanced NSCLC still is controversial, outcomes following 2-drug 
combination treatment in this subpopulation were explored.
Methods: In the main study of 432 randomized patients, median age 
was 67 years, 20% were ≥ 75 years old, 71% had stage IV disease 
and 28% PS 2. The PS2 subpopulation consisted of 123 patients, 62 
in the VC and 61 in the GC arm. The total PS2 group and subgroups 
according to treatment were analyzed with respect to survival, QOL, 
and toxicity including required interventions. The PS2 group was then 
compared to PS0/1 with respect to the same variables. 
Results: Follow-up time was minimum two years. Baseline charac-
teristics were well balanced between PS2 and PS0/1. Planned treat-
ment (three cycles) was completed in 68 % of PS2 versus 85% of 
PS0/1 patients (p<0.01), and reasons for drop-out were similar in the 
two subgroups. Median, 1-year and 2-year survival was lower in the 
PS2 group, 4.5 vs. 8.9 months, 10 % vs. 37 % and 2 % vs. 8.5 %, 
respectively (p<0.01). Patients with PS2 received signiﬁcantly less 
palliative radiotherapy and second-line chemotherapy than the PS0/1 
patients. Compared to PS0/1, PS2 patients had lower mean hemoglobin 
(p<0.01), more need of blood transfusions (p<.01), and more registered 
hospital admissions due to side effects (p=0.02). Regarding QOL, PS2 
patients had signiﬁcantly lower compliance regarding questionnaire 
completion and they had more cancer related symptoms at baseline. 
But global QOL improved and they achieved clinically meaningful pain 
relief during and after treatment. 
Conclusions: As expected, patients with PS2 had shorter survival, 
more anemia and more admissions due to side-effects. More important 
is that chemotherapy led to improved QOL also in PS2 patients.
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Prolonged infusion (PI) of gemcitabine (G) in combination with 
cisplatin (C) in patients with advanced non-small cell lung cancer 
(NSCLC): prelimininary results of measurement of g and its 
metabolites in plasma and white blood cells (WBC)
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Background: G and C combination is a common treatment in ad-
vanced NSCLC. G activity is mediated by intracellular concentration 
of di- and triphosphate derivates (dFdCTP), which is dose dependent. 
High plasma levels of G are achieved by prolonged infusion, holding 
a ﬁxed dose rate (FDR) of 10 mg/smq/min. In a previous pharmacoki-
netic (PK) study, with G 600 to 1200 mg/smq, at FDR of 10 mg/smq/
min, the target 15μM plasma concentration was achieved in 70% of pts 
at 600-900 mg/smq, but only in 44,4% at 1000-1200 mg/smq. Objec-
tive response rate was 56.5% vs 46.1% among pts receiving < 1000 or 
≥ 1000 mg/m2 respectively [Lung Cancer 2003; 41(S2):230]. Based on 
these ﬁndings, we have measured both plasma and intracellular concen-
tration of G, and its metabolites, at the doses of 600 and 1200 mg/smq, 
PI, aimed to correlate the plasmatic to the intracellular concentration.
Methods: G was administered on days 1 and 8, by an electronic pump, 
at a FDR of 10 mg/smq/min. DDP 75 mg/smq was administered on day 
8. Four pts received G at 600 mg/smq during the ﬁrst and 1200 mg/smq 
during the subsequent cycles. Four pts received 1200 mg/smq during 
all treatment. For PK evaluation, 8 blood samples were collected at 
speciﬁc intervals (from 0 to 24 hours) on the days 1 and 8 of the ﬁrst 
two chemotherapy courses, for a total of 32 samples per patient. G and 
its metabolites levels were determined by a validated HPLC-tandem 
mass spectrometry method. The intracellular levels of dFdCTP were 
determined by HPLC-UV in the WBC of treated pts.
Results: Each infusion achieved the steady state concentration in all 
patients, with G half-life consistently lower than 30 minutes. Target 
plasma concentration of 15 μM was achieved in all courses, among 
patients treated with 600 mg/smq and in 14/16 courses, among those 
treated with 1200 mg/smq (range D1: 17.1-64.2 μM; D8: 15-39.8 μM). 
G pharmacokinetic was not affected by DDP. Intracellular dFdCTP 
was already detectable 15 min after the start of infusion in all pts. The 
dFdCTP concentrations at the end of the infusion were substantial. The 
accumulation of dFdCTP with respect to time was prolonged beyond 
G infusion in all pts, except 3 of the 600 mg/smq group. Overall, the 
Cmax was reached at a median of 4 hours from the end of G admin-
istration. The within-patient comparisons (600 vs 1200 mg/smq and 
1200 vs 1200 mg/smq) did not show any inﬂuence of dose or number 
of administered courses. The inter-patient comparisons (600 vs 1200 
mg/smq) failed to show any signiﬁcant difference as well. 
Conclusions: It appears from this study that G prolonged infusion, at 
a FDR of 10 mg/smq/min, may provide a therapeutic 15μM plasma 
G concentration to the large majority of patients. Both plasma and 
intracellular G concentrations over the time do not seem inﬂuenced by 
the dose or the number of G administrations (within the ﬁrst 4), nor by 
DDP. Intracellular pharmacokinetic parameters and intergroup statisti-
cal evaluations are in progress.
